Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH.

Wang TF, Zwicker JI, Ay C, Pabinger I, Falanga A, Antic D, Noble S, Khorana AA, Carrier M, Meyer G.

J Thromb Haemost. 2019 Oct;17(10):1772-1778. doi: 10.1111/jth.14564. Epub 2019 Jul 28. No abstract available.

PMID:
31353841
2.

Adjuvant low-dose rituximab and plasma exchange for acquired TTP.

Zwicker JI, Muia J, Dolatshahi L, Westfield LA, Nieters P, Rodrigues A, Hamdan A, Antun AG, Metjian A, Sadler JE; ART Investigators.

Blood. 2019 Sep 26;134(13):1106-1109. doi: 10.1182/blood.2019000795. Epub 2019 Jul 22. No abstract available.

PMID:
31331919
3.

Anticoagulation in the Setting of Primary and Metastatic Brain Tumors.

Mantia C, Zwicker JI.

Cancer Treat Res. 2019;179:179-189. doi: 10.1007/978-3-030-20315-3_12. Review.

PMID:
31317488
4.

Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer.

Zwicker JI, Schlechter BL, Stopa JD, Liebman HA, Aggarwal A, Puligandla M, Caughey T, Bauer KA, Kuemmerle N, Wong E, Wun T, McLaughlin M, Hidalgo M, Neuberg D, Furie B, Flaumenhaft R; CATIQ Investigators11.

JCI Insight. 2019 Feb 21;4(4). pii: 125851. doi: 10.1172/jci.insight.125851. eCollection 2019 Feb 21.

5.

Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors.

Carney BJ, Uhlmann EJ, Puligandla M, Mantia C, Weber GM, Neuberg DS, Zwicker JI.

J Thromb Haemost. 2019 Jan;17(1):72-76. doi: 10.1111/jth.14336. Epub 2018 Dec 11.

PMID:
30450803
6.

Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: A systematic review.

Samuelson Bannow BR, Lee AYY, Khorana AA, Zwicker JI, Noble S, Ay C, Carrier M.

Res Pract Thromb Haemost. 2018 Jun 19;2(4):664-669. doi: 10.1002/rth2.12111. eCollection 2018 Oct.

7.

Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.

Kraaijpoel N, Di Nisio M, Mulder FI, van Es N, Beyer-Westendorf J, Carrier M, Garcia D, Grosso M, Kakkar AK, Mercuri MF, Middeldorp S, Hernandez CR, Santamaria A, Schwocho L, Segers A, Verhamme P, Wang TF, Weitz JI, Zhang G, Zwicker JI, Büller HR, Raskob GE.

Thromb Haemost. 2018 Aug;118(8):1439-1449. doi: 10.1055/s-0038-1667001. Epub 2018 Jul 30.

PMID:
30060256
8.

Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH.

Samuelson Bannow BT, Lee A, Khorana AA, Zwicker JI, Noble S, Ay C, Carrier M.

J Thromb Haemost. 2018 Jun;16(6):1246-1249. doi: 10.1111/jth.14015. Epub 2018 May 8. No abstract available.

PMID:
29737593
9.

The intersection of protein disulfide isomerase and cancer associated thrombosis.

Stopa JD, Zwicker JI.

Thromb Res. 2018 Apr;164 Suppl 1:S130-S135. doi: 10.1016/j.thromres.2018.01.005. Review.

10.

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.

Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang TF, Yeo E, Zhang G, Zwicker JI, Weitz JI, Büller HR; Hokusai VTE Cancer Investigators.

N Engl J Med. 2018 Feb 15;378(7):615-624. doi: 10.1056/NEJMoa1711948. Epub 2017 Dec 12.

11.

Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin.

Mantia C, Uhlmann EJ, Puligandla M, Weber GM, Neuberg D, Zwicker JI.

Blood. 2017 Jun 22;129(25):3379-3385. doi: 10.1182/blood-2017-02-767285. Epub 2017 May 3.

PMID:
28468796
12.

Risking thromboembolism: podoplanin and glioma.

Zwicker JI.

Blood. 2017 Mar 30;129(13):1742-1743. doi: 10.1182/blood-2017-02-763524. No abstract available.

PMID:
28360357
13.

Protein disulfide isomerase inhibition blocks thrombin generation in humans by interfering with platelet factor V activation.

Stopa JD, Neuberg D, Puligandla M, Furie B, Flaumenhaft R, Zwicker JI.

JCI Insight. 2017 Jan 12;2(1):e89373. doi: 10.1172/jci.insight.89373.

14.

Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions.

Rosenblatt J, Stone RM, Uhl L, Neuberg D, Joyce R, Levine JD, Arnason J, McMasters M, Luptakova K, Jain S, Zwicker JI, Hamdan A, Boussiotis V, Steensma DP, DeAngelo DJ, Galinsky I, Dutt PS, Logan E, Bryant MP, Stroopinsky D, Werner L, Palmer K, Coll M, Washington A, Cole L, Kufe D, Avigan D.

Sci Transl Med. 2016 Dec 7;8(368):368ra171.

15.

A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation: reply.

Zwicker JI, Carrier M.

J Thromb Haemost. 2016 Oct;14(10):2082. doi: 10.1111/jth.13429. Epub 2016 Aug 24. No abstract available.

16.

Scattering the spotlight on microparticles.

Zwicker JI.

J Thromb Haemost. 2017 Jan;15(1):185-186. doi: 10.1111/jth.13552. Epub 2016 Nov 28. No abstract available.

17.

A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation.

Zwicker JI, Karp Leaf R, Carrier M.

J Thromb Haemost. 2016 Sep;14(9):1736-40. doi: 10.1111/jth.13387. Epub 2016 Jul 29.

18.

Intracranial hemorrhage in cancer patients treated with anticoagulation.

Weinstock MJ, Uhlmann EJ, Zwicker JI.

Thromb Res. 2016 Apr;140 Suppl 1:S60-5. doi: 10.1016/S0049-3848(16)30100-1. Review.

PMID:
27067980
19.

Revisiting the mechanistic basis of the French Paradox: Red wine inhibits the activity of protein disulfide isomerase in vitro.

Galinski CN, Zwicker JI, Kennedy DR.

Thromb Res. 2016 Jan;137:169-173. doi: 10.1016/j.thromres.2015.11.003. Epub 2015 Nov 7.

20.

Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study.

Donato J, Campigotto F, Uhlmann EJ, Coletti E, Neuberg D, Weber GM, Zwicker JI.

Blood. 2015 Jul 23;126(4):494-9. doi: 10.1182/blood-2015-02-626788. Epub 2015 May 18.

21.

Yttrium-90 ibritumomab tiuxetan followed by rituximab maintenance as treatment for patients with diffuse large B-cell lymphoma are not candidates for autologous stem cell transplant.

Arnason JE, Luptakova K, Rosenblatt J, Tzachanis D, Avigan D, Zwicker JI, Levine J, Kim M, Parker JA, Grant B, Joyce RM.

Acta Haematol. 2015;133(4):347-53. doi: 10.1159/000368291. Epub 2015 Feb 7.

PMID:
25677780
22.

Prevention of venous thromboembolism in cancer outpatients: guidance from the SSC of the ISTH: reply.

Khorana AA, Zwicker JI, Connolly GC, Pabinger I.

J Thromb Haemost. 2015 Feb;13(2):325-6. doi: 10.1111/jth.12794. Epub 2014 Dec 16. No abstract available.

23.

Transfusion-associated Anaplasma phagocytophilum infection in a pregnant patient with thalassemia trait: a case report.

Shields K, Cumming M, Rios J, Wong MT, Zwicker JI, Stramer SL, Alonso CD.

Transfusion. 2015 Apr;55(4):719-25. doi: 10.1111/trf.12908. Epub 2014 Nov 11.

PMID:
25385549
24.

The reply.

Carrier M, Khorana AA, Zwicker JI.

Am J Med. 2014 Oct;127(10):e13. doi: 10.1016/j.amjmed.2014.07.019. No abstract available.

PMID:
25311068
25.

How long is long enough? Extended anticoagulation for the treatment of cancer-associated deep vein thrombosis.

Zwicker JI, Bauer KA.

J Clin Oncol. 2014 Nov 10;32(32):3596-9. doi: 10.1200/JCO.2014.56.5184. Epub 2014 Sep 29.

PMID:
25267753
26.

Prevention of venous thromboembolism in cancer outpatients: guidance from the SSC of the ISTH.

Khorana AA, Otten HM, Zwicker JI, Connolly GC, Bancel DF, Pabinger I; Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis.

J Thromb Haemost. 2014 Nov;12(11):1928-31. doi: 10.1111/jth.12725. Epub 2014 Sep 30. No abstract available.

27.

Therapeutic implications of protein disulfide isomerase inhibition in thrombotic disease.

Flaumenhaft R, Furie B, Zwicker JI.

Arterioscler Thromb Vasc Biol. 2015 Jan;35(1):16-23. doi: 10.1161/ATVBAHA.114.303410. Epub 2014 Aug 7. Review. Erratum in: Arterioscler Thromb Vasc Biol. 2015 Apr;35(4):e18.

28.

The reply.

Carrier M, Khorana AA, Zwicker JI.

Am J Med. 2014 Jul;127(7):e35. doi: 10.1016/j.amjmed.2014.03.020. No abstract available.

PMID:
24970611
29.

Unconventional approaches to the prevention of cancer associated thrombosis.

Zwicker JI.

Thromb Res. 2014 May;133 Suppl 2:S44-8. doi: 10.1016/S0049-3848(14)50008-4. Review.

PMID:
24862145
30.

Pattern of frequent but nontargeted pharmacologic thromboprophylaxis for hospitalized patients with cancer at academic medical centers: a prospective, cross-sectional, multicenter study.

Zwicker JI, Rojan A, Campigotto F, Rehman N, Funches R, Connolly G, Webster J, Aggarwal A, Mobarek D, Faselis C, Neuberg D, Rickles FR, Wun T, Streiff MB, Khorana AA.

J Clin Oncol. 2014 Jun 10;32(17):1792-6. doi: 10.1200/JCO.2013.53.5336. Epub 2014 May 5.

31.

Catheter-associated deep vein thrombosis of the upper extremity in cancer patients: guidance from the SSC of the ISTH.

Zwicker JI, Connolly G, Carrier M, Kamphuisen PW, Lee AY.

J Thromb Haemost. 2014 May;12(5):796-800. doi: 10.1111/jth.12527. No abstract available.

32.

Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH: a reply to a rebuttal.

Carrier M, Khorana AA, Zwicker JI, Noble S, Lee AY; Subcommittee on Haemostasis and Malignancy for the SSC of the ISTH.

J Thromb Haemost. 2014 Jan;12(1):116-7. doi: 10.1111/jth.12444. No abstract available.

33.

Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer.

Carrier M, Khorana AA, Moretto P, Le Gal G, Karp R, Zwicker JI.

Am J Med. 2014 Jan;127(1):82-6.e1. doi: 10.1016/j.amjmed.2013.09.015. Epub 2013 Oct 5.

PMID:
24384102
34.

Venous thromboembolism in cancer clinical trials: recommendation for standardized reporting and analysis.

Carrier M, Khorana AA, Zwicker JI, Lyman GH, Le Gal G, Lee AY; subcommittee on Haemostasis and Malignancy for the SSC of the ISTH.

J Thromb Haemost. 2012 Dec;10(12):2599-601. No abstract available.

PMID:
23362524
35.

Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study).

Zwicker JI, Liebman HA, Bauer KA, Caughey T, Campigotto F, Rosovsky R, Mantha S, Kessler CM, Eneman J, Raghavan V, Lenz HJ, Bullock A, Buchbinder E, Neuberg D, Furie B.

Br J Haematol. 2013 Feb;160(4):530-7. doi: 10.1111/bjh.12163. Epub 2012 Dec 13.

36.

Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis.

Mantha S, Karp R, Raghavan V, Terrin N, Bauer KA, Zwicker JI.

BMJ. 2012 Aug 7;345:e4944. doi: 10.1136/bmj.e4944. Review.

37.

Lenalidomide enhances anti-myeloma cellular immunity.

Luptakova K, Rosenblatt J, Glotzbecker B, Mills H, Stroopinsky D, Kufe T, Vasir B, Arnason J, Tzachanis D, Zwicker JI, Joyce RM, Levine JD, Anderson KC, Kufe D, Avigan D.

Cancer Immunol Immunother. 2013 Jan;62(1):39-49. doi: 10.1007/s00262-012-1308-3. Epub 2012 Jun 24.

38.

Accounting for death as a competing risk in cancer-associated thrombosis studies.

Campigotto F, Neuberg D, Zwicker JI.

Thromb Res. 2012 Apr;129 Suppl 1:S85-7. doi: 10.1016/S0049-3848(12)70023-3.

PMID:
22682141
39.

Biased estimation of thrombosis rates in cancer studies using the method of Kaplan and Meier.

Campigotto F, Neuberg D, Zwicker JI.

J Thromb Haemost. 2012 Jul;10(7):1449-51. doi: 10.1111/j.1538-7836.2012.04766.x. No abstract available.

40.

Pulmonary zygomycosis in a non-neutropenic patient with myelodysplastic syndrome on lenalidomide.

Theisen-Toupal J, Rosenthal ES, Kelly E, Zwicker JI, Akuthota P, Roberts DH.

Respir Care. 2012 Jul;57(7):1175-7. doi: 10.4187/respcare.01346. Epub 2012 Feb 24.

41.

Measurement of platelet microparticles.

Zwicker JI, Lacroix R, Dignat-George F, Furie BC, Furie B.

Methods Mol Biol. 2012;788:127-39. doi: 10.1007/978-1-61779-307-3_10.

PMID:
22130705
42.

Tissue factor-bearing microparticles and thrombus formation.

Zwicker JI, Trenor CC 3rd, Furie BC, Furie B.

Arterioscler Thromb Vasc Biol. 2011 Apr;31(4):728-33. doi: 10.1161/ATVBAHA.109.200964. Epub 2011 Jan 20. Review.

43.

Impedance-based flow cytometry for the measurement of microparticles.

Zwicker JI.

Semin Thromb Hemost. 2010 Nov;36(8):819-23. doi: 10.1055/s-0030-1267035. Epub 2010 Nov 3. Review.

PMID:
21049382
44.

Predictive value of tissue factor bearing microparticles in cancer associated thrombosis.

Zwicker JI.

Thromb Res. 2010 Apr;125 Suppl 2:S89-91. doi: 10.1016/S0049-3848(10)70022-0. Review.

PMID:
20434015
45.

Low molecular weight heparin to achieve live birth following unexplained pregnancy loss: a systematic review.

Mantha S, Bauer KA, Zwicker JI.

J Thromb Haemost. 2010 Feb;8(2):263-8. doi: 10.1111/j.1538-7836.2009.03687.x. Epub 2009 Nov 13. Review.

46.

Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy.

Zwicker JI, Liebman HA, Neuberg D, Lacroix R, Bauer KA, Furie BC, Furie B.

Clin Cancer Res. 2009 Nov 15;15(22):6830-40. doi: 10.1158/1078-0432.CCR-09-0371. Epub 2009 Oct 27.

47.

Tissue factor-bearing microparticles and cancer.

Zwicker JI.

Semin Thromb Hemost. 2008 Mar;34(2):195-8. doi: 10.1055/s-2008-1079260. Review.

PMID:
18645925
48.

Timing of postpartum enoxaparin administration and severe postpartum hemorrhage.

Freedman RA, Bauer KA, Neuberg DS, Zwicker JI.

Blood Coagul Fibrinolysis. 2008 Jan;19(1):55-9. doi: 10.1097/MBC.0b013e3282f185dd.

PMID:
18180616
49.

Cancer-associated thrombosis.

Zwicker JI, Furie BC, Furie B.

Crit Rev Oncol Hematol. 2007 May;62(2):126-36. Epub 2007 Feb 12. Review.

PMID:
17293122
50.

The thrombospondin-1 N700S polymorphism is associated with early myocardial infarction without altering von Willebrand factor multimer size.

Zwicker JI, Peyvandi F, Palla R, Lombardi R, Canciani MT, Cairo A, Ardissino D, Bernardinelli L, Bauer KA, Lawler J, Mannucci P.

Blood. 2006 Aug 15;108(4):1280-3. Epub 2006 May 9.

Supplemental Content

Loading ...
Support Center